ciclesonide
Brand: Alvesco (inhaled), Omnaris (nasal), Zetonna (nasal)
Prototype: fluticasone propionate
Drug Class: inhaled corticosteroid (ICS)
Drug Family: corticosteroid
Subclass: prodrug ICS — airway-activated glucocorticoid
Organ Systems: respiratory
Mechanism of Action
Prodrug converted by airway esterases to the active metabolite des-ciclesonide (des-CIC) with high topical glucocorticoid potency; des-CIC binds GR in airway inflammatory cells and epithelium, reducing airway inflammation; low systemic bioavailability due to high protein binding and rapid hepatic inactivation minimizes systemic adverse effects.
glucocorticoid receptor (GR)airway epithelial esterases
Indications
- persistent asthma in adults and adolescents (inhaled)
- allergic rhinitis (nasal)
Contraindications
- acute asthma exacerbations
- hypersensitivity to ciclesonide
Adverse Effects
Common
- headache
- nasopharyngitis
- sinusitis (minimal oropharyngeal candidiasis due to prodrug activation in airway)
Serious
- adrenal suppression (high-dose prolonged use)
- growth suppression
- osteoporosis
Pharmacokinetics (ADME)
| Absorption | inhaled; converted to active des-ciclesonide by airway esterases; systemic bioavailability approximately 11-22% (primarily swallowed portion converted by gut/liver); low oral bioavailability of parent drug (<1%) |
| Distribution | des-CIC 99% protein bound; Vd approximately 2.9 L/kg |
| Metabolism | prodrug activation in airways and GI tract; hepatic CYP3A4 and CYP2D6 metabolism of des-CIC |
| Excretion | fecal (~66%) and renal (~20%) |
| Half-life | approximately 3.5 hours (des-ciclesonide) |
| Onset | anti-inflammatory within days; maximal benefit over weeks |
| Peak | 1-2 hours |
| Duration | 24 hours |
| Protein Binding | 99% (des-CIC) |
| Vd | approximately 2.9 L/kg |
Drug Interactions
| Drug / Agent | Mechanism | Severity |
|---|---|---|
| strong CYP3A4 inhibitors | may increase des-ciclesonide systemic levels; potential adrenal suppression | moderate |
| strong CYP3A4 inducers | may reduce des-ciclesonide levels and reduce asthma control | moderate |
Nursing Considerations
- Ciclesonide is one of the few ICS with minimal oropharyngeal candidiasis due to its prodrug design — activation primarily occurs in the lower airways, not the oropharynx; still instruct patients to rinse mouth to minimize any local deposition.
- Once-daily dosing (Alvesco) may improve adherence; patients should be reminded that once-daily dosing does not provide immediate relief of acute symptoms.
- Monitor for systemic corticosteroid effects particularly in patients receiving high doses or concomitant nasal ICS (cumulative corticosteroid burden); screen annually for cataracts and assess bone density.
- Advise patients not to stop ICS abruptly; gradual step-down under medical supervision is recommended when asthma is well-controlled for 3 months.
Clinical Pearls
- Ciclesonide's prodrug mechanism results in site-specific activation in the lower airways, leading to one of the lowest rates of oropharyngeal candidiasis and dysphonia among ICS — a clinically meaningful advantage for patients with voice-dependent occupations.
- The very high lipid solubility and protein binding of des-ciclesonide creates a pulmonary depot effect — the drug concentrates in lung tissue and is slowly released, supporting once-daily dosing despite a relatively short plasma half-life.
Safety Profile
Pregnancy use-with-caution
Lactation insufficient-data
Renal Adjustment Not required
Hepatic Adjustment Not required
TDM Not required
Concordance Terms
Cross-referenced clinical concepts — click any term to see all content where it appears.